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PARDIOVASCULAR GENOMIC MEDICINE
enomics and Cardiac Arrhythmias
obert Roberts, MD, FACC
ttawa, Ontario, Canada
Sudden cardiac death in patients younger than 35 years of age is primarily due to genetic
causes. Familial hypertrophic cardiomyopathy accounting for 30% to 40% is associated with
structural heart disease while the Brugada syndrome and the long QT syndrome (LQTS) are
associated with normal cardiac function. This is a review of the genetics of supraventricular
and ventricular arrhythmias. Atrial fibrillation is mapped to nine chromosomal loci and four
genes are identified. Adenosine monophosphate-activated protein kinase is one gene
responsible for Wolff-Parkinson-White syndrome. The LQTS and the Brugada syndromes
are due to defects primarily in cardiac sodium and potassium ion channels. The role of single
nucleotide polymorphisms in predisposing to arrhythmias in acquired disorders such as
hypertrophy is discussed. (J Am Coll Cardiol 2006;47:9–21) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.059College of Cardiology Foundation
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mhe past decade has been golden for cardiovascular diseases
ith the elucidation of several genes responsible for familial
ardiomyopathies and the ion channelopathies. However,
hese diseases, referred to as single gene disorders, were
menable to chromosomal mapping of the gene locus
hrough conventional genetic linkage analysis. In these
isorders, a single gene predominates in the expression of
he phenotype. However, even with single gene disorders,
here are modifier genes, which have a significant influence
n the phenotype but would not be detected by this
onventional technique. There is suggestive evidence that
rrhythmias such as atrial fibrillation occurring in associa-
ion with acquired structural heart disease are more likely in
hose individuals with genetic predisposition (1,2). This is
articularly pertinent in polygenic diseases such as coronary
rtery disease and hypertension (3,4). Locating and identi-
ying modifier genes and genes that predispose but do not
er se induce the phenotype has not been feasible due to
ack of appropriate statistical models and high throughput
enotyping technology. While both of these problems are
till with us, there are currently methods making it possible
nd practical to pursue such research goals.
The sequencing of the human genome has brought with
t a wealth of information as well as enabling the develop-
ent of high throughput technology. It is now recognized
hat 99.9% of the three billion bases that comprise the
uman genome are identical (5,6). Thus, about three
illion bases account for all of the differences between
uman beings including one’s resistance or vulnerability to
isease. The current and future challenge is to identify these
ifferences referred to as single nucleotide polymorphisms
SNPs). Currently, it appears there are over 15 million
NPs circulating in the population from which three mil-
ion can be selected to be passed on by each parent to their
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ccepted August 17, 2005.ffspring. A major project referred to as the HapMap
roject is ongoing to map the chromosomal location of
hese SNPs and generate haplotypes involving multiple
NPs that tend to be inherited as blocks or units (7). The
ffect of SNPs on a particular phenotype may be through
aplotypes containing several SNPs rather than a single
NP. To identify these SNPs or haplotypes on a genome-
ide basis for a particular phenotype such as atrial fibrilla-
ion would require hundreds of thousands of DNA markers,
hich, until recently, would be prohibited (6). Chips are
ow available with hundreds of thousands of SNPs such as
he Affymetrix 500,000 chip (Affymetrix, Santa Clara,
alifornia) to perform these studies. Secondly, such high-
ensity DNA markers make it possible to utilize mathemat-
cal models to identify associations with polymorphisms that
ave minimal effect on the phenotype (5,6,8). It is now
ossible to genotype 100 DNA samples for 500,000 geno-
ypes over a period of a few hours. This has ushered in a new
ra for detecting genetic variants that affect human disease.
ENOMIC IMPLICATIONS FOR DIAGNOSIS AND
REATMENT OF SUDDEN CARDIAC DEATH (SCD)
udden cardiac death remains a worldwide scourge. There
re considerable data to indicate the proximate cause of
CD is electrical due to cardiac conduction defects or
ysrhythmias. In the U.S. over 400,000 and in Canada over
0,000 die annually from SCD (9). It is of note that this
umber has not changed for the past three decades. Thus,
reatment for SCD has not been as progressive as in other
orms of cardiac disease, indeed one may say it has been
egressive. A major landmark study evaluating drugs in the
reatment of arrhythmias was the international clinical trial
eferred to as Cardiac Arrhythmia Suppression Trial
CAST) (10). The major and unexpected finding was that
ost of the drugs used in the trial were shown to be
ro-arrhythmic. Quinidine, a drug used for decades in the
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Genomics and Cardiac Arrhythmias January 3, 2006:9–21reatment of supraventricular and ventricular arrhythmias
as shown to prolong the QT interval and induce ventric-
lar arrhythmias and SCD. Therapy had to be developed
mpirically without knowing the molecular basis for the
isease or the molecular mechanism of the drug. Current
nowledge of ion channels facilitates the development of
rugs without known adverse effects such as prolongation of
he QT. It is expected that genetic defects, many of which
nvolve ion channels, will help to identify molecular mech-
nisms for arrhythmias, which are also applicable to ar-
hythmias caused by acquired disease. There is some en-
ouragement with the overlap between the mechanism
esponsible for ventricular tachycardia of familial long QT
yndrome (LQTS) and that induced by quinidine in ac-
uired disorders.
Young individuals who die with monogenic disorders
uch as Brugada syndrome or prolonged QT syndrome are
sually asymptomatic, and SCD is their first and often last
ymptom. In the future, when appropriate therapy becomes
vailable to prevent SCD in the asymptomatic individuals,
enetic screening will be a prerequisite (e.g., Brugada
yndrome, LQTS, and so on). Gene testing on the basis of
amily history or an incidental electrocardiogram (ECG)
nding (e.g., insurance) followed by appropriate therapy is
ikely to be a future routine to prevent SCD. Most of SCD
ver the age of 35 years occurs in association with acquired
tructural heart disease and symptoms. There is, however,
he concern of who is vulnerable for SCD. For example, in
eart failure 50% die of SCD due to arrhythmias (11). The
nly effective treatment is an indwelling defibrillator. The
ilemma is identifying which half is vulnerable. One hope is
o detect SNPs that predispose to SCD. Identifying molec-
lar defects responsible for arrhythmias should lead to novel
herapies specifically designed to target the abnormality.
dentification of the defect in the cholesterol receptor of
amilial hypercholesterolemia leads to the development of
rugs (statins) to inhibit cholesterol synthesis. These drugs
re now the mainstay of treatment to prevent coronary
rtery disease in the general population. Pharmacogenetics
nd pharmacogenomics will assist in selecting the drug and
etermining the dose on an individual basis to minimize
dverse side effects. Determining who is at risk for arrhyth-
Abbreviations and Acronyms
AMPK adenosine monophosphate-activated protein
kinase
AP  action potential
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LQTS  long QT syndrome
SCD  sudden cardiac death
SNP  single nucleotide polymorphism
SQTS  short QT syndrome
WPW  Wolff-Parkinson-White syndromeias and SCD is a problem common to those with ttructural or electrical cardiac disease. The person without
tructural heart disease (Brugada syndrome) is perhaps at a
reater disadvantage because they are more likely to be
ounger and less likely to have a reason to visit the
hysician.
HE FREQUENCY AND PREVALENCE
F GENETIC-INDUCED ARRHYTHMIAS
n considering the role of genetics and arrhythmias, one
ust pause as to the frequency and prevalence of the
enetic-induced arrhythmias. Throughout the world, SCD
ccurring in the young adult (35 years) whether associated
ith structural or nonstructural heart disease is predomi-
antly due to genetic defects. Familial hypertrophic cardio-
yopathy (HCM) with a prevalence of 1 in 500 is the most
ommon cause of SCD in the young (12). While there are
o population studies on the prevalence of the genotype,
stimates based on the phenotype, which usually underes-
imates the genotype, show it is very common for a genetic
isorder. It is estimated over 12 million individuals in the
orld carry the genetic defect for HCM. There are over
00,000 individuals with this genetic defect in the U.S. and
0,000 in Canada. Brugada syndrome, another familial
ause of SCD in the young, is the most common cause of
CD occurring in individuals without structural heart dis-
ase (13). Wolff-Parkinson-White syndrome (WPW) is the
econd most common cause of supraventricular arrhythmias
n the Western world and the most common cause in China
14). The role of WPW in SCD remains controversial. In
hose studies in which the cardiac conduction system was
valuated, WPW was a major cause of SCD, particularly in
nfants (15). Wolff-Parkinson-White syndrome, while al-
ays a genetic disease, appears to be mostly sporadic rather
han familial. In a recent study, 30% of patients with atrial
brillation with or without structural heart disease had a
amily history of atrial fibrillation (16). Offspring with even
single parent having atrial fibrillation will have 85%
ncreased risk of developing atrial fibrillation (16). For
ingle gene disorders, many genes with their corresponding
utations have been identified, and the appropriate tech-
ology could be assembled soon to screen populations at risk
f having these genetic defects.
HE ROLE OF GENETICS IN ACQUIRED ARRHYTHMIAS
n the middle-aged and elderly population, which accounts
or most of SCD, the cause is almost always associated with
tructural heart disease predominantly due to coronary
rtery disease. What is the role of genetic defects in these
ndividuals? While no gene or polymorphism has yet been
efinitely identified to induce arrhythmias, there is increas-
ng evidence that genetic predisposition contributes signif-
cantly to acquired arrhythmias (17). For example, a recent
nding shows that atrial fibrillation occurring with struc-
ural and nonstructural heart disease is associated with a
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January 3, 2006:9–21 Genomics and Cardiac Arrhythmiasamily history of atrial fibrillation in 30% of patients (16).
uch of susceptibility to acquired disease is thought to be
ncoded primarily by SNPs that span the human genome.
ven in single gene disorders, there are modifying genes
SNPs), which modulate the phenotype resulting from the
nteraction of the environment with the genotype. A third
roup of genes modulating arrhythmias in acquired and
nherited diseases, particularly coronary artery disease or
eart failure, are those whose expression is reprogrammed
y the underlying disease. An excellent and well-
haracterized example is cardiac compensatory hypertrophy
n response to pressure overload as occurs in hypertension,
alvular disease, or heart failure. In pathological hypertro-
hy as opposed to physiological hypertrophy, expression of
host of genes is up-regulated as part of the so-called fetal
rogram (18). The extent of hypertrophy may, in part,
epend on the presence or absence of certain alleles. For
xample, regardless of the cause, if the patient is homozy-
ous for the DD allele of the angiotensin-converting en-
yme gene as apposed to the I-form, hypertrophy will be
ore extensive and the propensity for SCD greatly in-
reased (19). Hypertrophy that deteriorates into dilated
ardiomyopathy induces the expression of other genes,
hich could alter the predisposition to atrial or ventricular
rrhythmias and SCD. All of the association studies sug-
esting genetic predisposition remain suspect because of the
mall sample size (6), but the technology is now available to
ursue studies with adequate sample size. The availability of
enome-wide scans with 500,000 SNPs properly selected is
ikely to add a new dimension to our search for genetic
redisposition and modifier genes.
ENETIC SCREENING FOR PREDICTION
ND PREVENTION OF ARRYTHMIAS
enes themselves do not engage in the work of the cell, but
ather their end product, the protein, performs the function
f the organism. In single gene disorders of adults, the most
ommon mutation is a missense. This is a genetic defect in
hich a single base has been substituted for another
esulting in the encoding of a different amino acid, which, if
ccurring in an important domain of the protein, will be
ssociated with a gain- or loss-of-function. Other less
ommon defects would be a loss or gain of a base resulting
n a protein with many amino acids altered or the coding
ay be changed to a start or stop codon resulting in a
runcated protein. Genetic defects occurring in non-protein
oding regions will be manifested primarily as increased or
ecreased expression of the protein. Thus, the major func-
ional change in the protein is loss- or gain-of-function due
o an alteration in the amino acid composition or the
xpression of the protein. While genetic screening is pivotal
n the prevention of genetic disease, it unfortunately is not
he only variable that must be considered. Genetic screening
etermines the presence or absence of the genetic defect and
hus whether there is a risk of developing the disease. dcreening for polymorphisms in polygenic disorders deter-
ines whether there is a risk of increased susceptibility for
rrhythmias. Other critical features must be considered as
e move into the genetic revolution and apply this infor-
ation to the care of patients. Despite having the genotype
t birth, several factors modulate whether the phenotype
ill ever develop and to what extent. First, is the feature of
enetrance which the risk of developing the phenotype in an
ndividual with the genetic defect. In the case of single gene
isorders, those that are autosomal dominant have a high
enetrance of probably 70% to 80% but seldom complete.
hus, a percentage of individuals despite having the defec-
ive gene do not develop the disease. The other modifier is
eferred to as expressivity defined as the variability in
henotypic manifestations that occur across a population
espite being due to the same genetic defect. The onset of
he phenotype is often age-dependent. The severity of the
henotype and whether it develops are also influenced by
nvironmental factors such as exercise, temperature, gender,
nd other factors. Nevertheless, solutions to these problems
ill be facilitated with routine genetic screening and in-
reased experience. Present knowledge clearly indicates that
multidisciplinary approach is required in the future to
dentify these genetic abnormalities and utilize them for
reatment and prevention. It does require careful clinical
haracterization, genetic expertise, functional analysis, and
enetic counseling along with drug discovery to significantly
mpact this worldwide scourge.
ENETICS OF SUPRAVENTICULAR ARRHYTHMIAS
trial fibrillation. Atrial fibrillation is the most common
ustained cardiac arrhythmia. It occurs in about 6% of the
opulation over the age of 60 years. It is estimated there are
ver 3 million people with persistent atrial fibrillation in the
.S. (20), which will increase to 5.6 million by 2050 (21).
t age 40 years and over, the chance of developing atrial
brillation in men and women is about 25% (22). It is
ssociated with significant morbidity and mortality, ac-
ounting for over one-third of all strokes over the age of 60
ears (23). In a recent Framingham Heart study of 2,243
articipants, 681 had at least one parent with atrial fibril-
ation (16). This indicates 30% of all patients with atrial
brillation, with or without structural heart disease, have a
amily history of the disease (16). The relative risk of atrial
brillation was increased 85% in individuals with at least
ne parent with a history of atrial fibrillation (16). We
dentified the first locus for familial atrial fibrillation on
hromosome 10 (10q22), confirming the inheritance of this
isease (24). Currently, seven chromosomal loci have been
apped and four of the genes identified. The genetic
eatures of each of these loci are summarized in Table 1, and
brief discussion will follow of each of the genes.
CNQ1 gene. KCNQ1, the first gene, was identified (25)
n a four-generation Chinese family showing autosomal
ominant inheritance. The loci was mapped to chromosome
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Genomics and Cardiac Arrhythmias January 3, 2006:9–211p15.5 and the gene, KCNQ1, encodes for the alpha
ubunit of a cardiac potassium channel. The mutation
onsisted of substitution of adenine to guanine at nucleotide
18 resulting in an amino acid substitution of serine for
lycine at residue 140 (S140g). Penetrance was close to
00%. Expression of the wild type and mutant KCNQ1
ene in COS cells showed increased potassium current
ensity. Thus, the mutation induced a gain-of-function,
hich shortens the atrial action potential (AP) duration and
he effective atrial refractory period. Several investigators
ith multiple families had shown KCNQ1 is not responsi-
le for atrial fibrillation in their families (26), suggesting this
s an uncommon cause for atrial fibrillation.
CNE2 gene. A second locus was identified by the same
hinese investigators (27) on 21q22 encoding for another
otassium channel subunit (KCNE2). The mutation was
hown to involve a C to T transition at nucleotide 79 of the
ene for KCNE2. This resulted in an arginine to cysteine at
esidue 27 (r27C), which is present in all affected individuals
ut not in healthy individuals. Mode of transmission was
gain, autosomal dominant. Functional studies, again,
howed that the mutant shortened the atrial AP duration
nd the atrial effective refractory period. The penetrance
ppeared to be incomplete although difficult to assess from
he limited number of studies performed.
CNJ2 gene. A third gene was identified in 30 unrelated
hinese kindred of atrial fibrillation showing a missense
utation in the potassium channel KCNJ2 (28). KCNJ2
ncodes for the Kir 2.1 channel, which mediates potassium
urrent in the heart. It is an inward rectifier, which induces
arly repolarization. The gene exhibited a missense muta-
ion with G to A at nucleotide 277 corresponding to a valine
o isoleucine at residue 93 (V93I) of the protein. Functional
nalysis again showed that this mutant gene shortens the
trial AP duration and the atrial refractory period. Overex-
ression of the wild type Kir 2.1 in the mouse induced atrial
brillation (29). Acquired atrial fibrillation in humans is
ssociated with increased expression of the Kir 2.1 channel
30–33). The investigators also analyzed KCNJ2 in 154
ther patients with lone atrial fibrillation, but no mutation
as identified (28).
CNH2 gene. Recently, Hong et al. (34) identified a
amily with short QT syndrome (SQTS) in whom three
embers presented with atrial fibrillation. The proband of
Table 1. Genetic Loci Responsible for Atrial F
Locus Gene
Mode of
Inheritance Mu
11p15.5 KCNQ1 AD S14
21q22 KCNE2 AD R2
17q KCNJ2 AD V9
7q35–36 KCNH2 AD N5
5p13 Unknown Recessive Un
6q14–16 Unknown AD Un
10q22 Unknown AD Un
AAP  atrial action potential duration; AD  autosomal d7 years of age presented with paroxysmal atrial fibrillation. gCNH2 gene exhibited a missense mutation at nucleotide
7645 with C going to G resulting in the substitution of
sparagine for lysine at residue 588 (N588K). All affected
embers upon electrophysiological testing showed a short-
ning of the atrial and ventricular refractory periods with
nducibility of atrial and ventricular fibrillation. The muta-
ion confers a gain-of-function with a shortening of the
trial AP duration and the effective atrial refractory period.
enetic defects provide insight into the mechanism for
trial fibrillation. There are several consistent features of
he genetics of atrial fibrillation:
) Genes identified all encode for subunits of potassium
channels
) All mutations confer a gain-of-function
) All of the mutations shorten the atrial AP duration and
the atrial effective refractory period
trial fibrillation is thus a channelopathy whereby the
enetic defects provide an ideal substrate for re-entry
rrhythmias. The consistency of the mechanism whereby
enetic defects induce atrial fibrillation should provide
pecific targets for the development of novel drug therapy.
OLYMORPHISMS THAT
REDISPOSE TO ATRIAL FIBRILLATION IN
NDIVIDUALS WITH STRUCTURAL HEART DISEASE
trial fibrillation occurs mostly in association with acquired
iseases such as coronary heart disease, value disease, or
eart failure. In a recent study (1) involving 250 patients
ith structural heart disease and atrial fibrillation, 250
ontrols expression of polymorphisms N235T, G-6A,
-217A of the angiotensin-converting enzyme gene were
ignificantly increased in patients with atrial fibrillation over
hat of controls with a p value of 0.01, 0.005, and 0.002,
espectively. The odds ratio for atrial fibrillation was 2.5
ith M235/M235  M235/T235 genotype, 3.3 for the
6/G6 genotype, and 2.0 for the G217/G217 genotype.
imilar associations have been made with polymorphisms in
he connexin 40 gene. This gene encodes a cardiac gap
unction protein, which mediates electrocoupling of cardio-
yocytes (2). The polymorphisms in the promoter region
pstream of the gene, which are 44A and 44AA
lation
n
Effect on
Function Physiological Effect
Gain of function 2 AAP 2 ARP
Gain of function 2 AAD 2 ARP
Gain of function 2 AAD 2 ARP
Gain of function 2 AAP 2 ARP
n Unknown Unknown
n Unknown Unknown
n Unknown Unknown
nt; ARP  atrial effective refractory period.ibril
tatio
0G
7C
31
88K
know
know
knowenotypes, were more frequent in subjects with atrial fibril-
l
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January 3, 2006:9–21 Genomics and Cardiac Arrhythmiasation exhibiting a risk ratio of 5.3 and 6.2, respectively, for
trial fibrillation. In another study (35), 108 patients with
cquired atrial fibrillation compared to controls showed the
38G alleles of connexin 40 exhibited an odds risk ratio for
trial fibrillation of 1.8 in patients with more than one
38G allele. These studies suggest that polymorphisms
redispose to atrial fibrillation when occurring in association
ith these diseases. It is important to recognize that these
tudies are case control association studies, and it is inade-
uate to make definitive conclusions. The sample size is too
ew and would require confirmation of the larger sample size
nd also better matching of controls with affected individ-
als. However, the availability recently of genome-wide
cans with hundreds of thousands of SNPs will, in the
uture, make it possible to perform genomic studies to
dentify SNPs that predispose to diseases such as atrial
brillation. This is expected to be a major onslaught of
enomic technology in the next few years.
aroxysmal supraventricular tachycardia. Wolff-Parkinson-
hite syndrome is the most common form of paroxysmal
upraventricular tachycardia in China and the second most
ommon cause in the Western world (14,36). The incidence
f WPW is about 1 in 3,000 of the population. This
yndrome, named after the individuals described in 1930,
as remained as a paradigm of a model for re-entry
rrhythmias. In this disease, there is an accessory bundle of
uscle tissue, which connects the atrium to the ventricle
ypassing the atrioventricular node. Conduction through
he accessory bundle is usually retrograde but under unusual
ircumstances may be antegrade at very rapid rates of 150
eats/min. Rapid heart rates, whether retrograde or ante-
rade, if sustained lead to heart failure or even ventricular
achycardia and SCD. The most common form of tachy-
ardia associated with WPW is paroxysmal supraventricular
achycardia with rates of 120 to 160 beats/min. The role of
PW in SCD is difficult to assess. Autopsies performed to
ssess cause of death do not examine the specialized con-
uction system of the heart and thus would not detect
PW. In studies in which the conduction system was
valuated, WPW was found to account for 33% of patients
ho died suddenly without structural heart disease (15).
he prevalence of familial WPW appears to be low with
ost due to a sporadic genetic defect; WPW is a genetic
isease in that the formation of an accessory conducting
undle or lack of remodeling of an existing bundle requires
enetic regulation. It is perhaps analogous to cancer, which
s an obligatory genetic disease, but the familial form
ppears less common.
In 2001 we identified a family with WPW and showed
37) the gene responsible for the disease in this family
ncodes for the gamma 2 subunit of the enzyme adenosine
onophosphate-activated protein kinase (AMPK). The
ene is referred to as PRKAG2 located on chromosome
q36 and is inherited in an autosomal dominant pattern;
MPK consists of three subunits, alpha, beta, and gamma,
ith each subunit encoded by a distinct gene. The gamma iubunit has a binding site for AMP, which is essential for
nzymatic activity. The mutation consists of a substitution
f glutamine for arginine at residue 302. Six mutations have
ince been described in several families all of which are
issense mutations except for one, which is an insertion
38). The penetrance based on the few families so far
tudied is in the range of 70% to 80%. The phenotype
onsists of pre-excitation on the ECG, varying degrees of
onduction defects, frequently cardiac hypertrophy, and
xcessive glycogen storage in the myocytes without sarco-
ere or myocyte disarray (39). The most common arrhyth-
ia associated with WPW is that of paroxysmal supraven-
ricular tachycardia with a narrow QRS. In the remaining
0%, the arrhythmia is generally atrial fibrillation. In this
yndrome, however, the incidence of atrial fibrillation is
uch higher in the range of 40% to 50%; AMPK is a sensor
f the body’s ATP level and is activated by an increase in the
atio of AMP to ATP (40,41). The availability of ATP is
ncreased by AMPK through increasing glucose absorption,
nhibiting glycogen synthesis, increasing fatty acid oxida-
ion, and decreasing fatty acid synthesis. Transgenic mice
xpressing either the R302q mutation (39) or the N4881
utation (42) exhibit a typical phenotype as observed in
umans for this disease. The mechanism whereby AMPK
eads to accessory pathways or alters conduction remains to
e determined. In one study, it has been shown that R302Q
utation inhibits the cardiac sodium inward current (41).
tilizing these transgenic models, studies are now being
erformed to determine alternate forms of therapy. It also
erves as a model to elucidate AMPK’s role in the develop-
ent of the heart and, in particular, that of the specialized
ardiac conduction system. The accepted form of treatment
urrently in patients with familial WPW is ablation of the
ccessory bundle. Therapy to prevent the excessive glycogen
torage may require replacement of AMPK enzyme.
ENETICS OF VENTRICULAR ARRHYTHMIAS
rugada syndrome. There remains a large group of indi-
iduals who develop idiopathic ventricular fibrillation unas-
ociated with any structural heart disease. In 1995, a disease
ow referred to as Brugada syndrome (43) was described,
hich is associated with SCD at a very young age and is
esponsible for a significant proportion of sudden infant
eath syndrome. Brugada syndrome is characterized by a
istory of sudden death and a typical ECG pattern of
T-segment elevation in leads V1 to V3 (Fig. 1) (13). It is
laimed to be responsible for up to 12% of all sudden deaths
nd approximately 20% of deaths occurring in patients with
tructurally normal hearts. In the Western world, the
revalence of this disease appears to be in the order of 1 in
,000 individuals. In Southeast Asia, the disease is more
revalent being a leading cause of death in males under the
ge of 40, second only to car accidents (13). This disease
xhibits an autosomal dominant pattern of inheritance
ndicating it affects men and women equally, and 50% of the
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Genomics and Cardiac Arrhythmias January 3, 2006:9–21ffspring will inherit the gene and be at risk of developing
rrhythmias and SCD. This also means only one copy of the
ene is defective, and it acts as a dominant positive or
egative. All of the mutations identified have been in a
ubunit of the sodium cardiac channel (SCN5A).
The subunit referred to as SCN5A has a genomic
tructure (44) consisting of 28 exons spanning approxi-
ately 80 kb on chromosome 3p21 with a dinucleotide
epeat polymorphism in entron 16. The gene encodes for a
rotein with 2,016 amino acids. Sodium channels, like most
on channels, are part of a complex. The pore forming alpha
ubunit is encoded by SCN5A, and up to three beta
ubunits have been described, as well as other attachments
o the cytoskeleton such as caveolas (45). The mutations
dentified responsible for the Brugada syndrome have been
rimarily missense mutations. More than 60 mutations have
een described in the SCN5A of which all have been
ocalized to the protein coding sequences. Screening for
hese mutations show they account for only about 25% of
atients with Brugada syndrome. This indicates there may
e other mutations in the SCN5A gene and most likely
utations in multiple other genes. Most of the genes
esponsible for the ion channels of the cardiac AP have been
loned and are available as good candidates to screen for
hese mutations. The mutations identified in SCN5A have
een associated with a loss of current either by creating a
runcated protein or by increasing sodium channel inactiva-
igure 1. Variation in the precordial lead ST and T waves in a patient with
’Rourke RA. Hurst’s The Heart. 11th edition. McGraw-Hill Companieion (13). One of the mutations, an insertion, occurred in the splicing donor site of intron 7. Recently, the first
ntronic mutation in SCN5A was described (46), which
nvolved a four base pair insertion in exon 27. This led to a
runcated protein and a non-functional channel. Brugada
yndrome and LQTS can both be caused by defects in the
CN5A but are opposite in function, namely, the former is
ue to loss of function leading to an accelerated inactivation
f the sodium channel resulting in more rapid depolariza-
ion (46). Patients with Brugada syndrome on becoming
ebrile are more likely to develop arrhythmias and SCD
13). It is evident there are many more mutations and other
enes yet to be discovered considering that over 75% of
ases are not due to known mutations. A second locus has
een mapped to chromosome 3 (13) indicating at least
nother gene; however, that gene has not been identified.
enetic screening, currently not available, will be essential
or the management of this disease because most of these
eople do not have symptoms. Even when someone is
dentified to have a history of this disease, it will be
ecessary to determine which 50% of the offspring have the
utation and are vulnerable to arrhythmias and SCD.
enetic screening is necessary for appropriate genetic coun-
eling as well as to implement preventive therapy when it
ecomes available. In the meantime, it is important to
ecognize that most drugs are not effective in this syndrome.
n implantable cardioverter-defibrillator (ICD) is essen-
ada syndrome. Reprinted with permission from Fuster V, Alexander RW,
04.ially the only recommended form of therapy.
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linical features. The congenital LQTS is an inherited
isease characterized by prolongation of ventricular repolar-
zation, which is manifested by prolongation of the QT
nterval on the ECG (47). It is associated with a high risk of
udden death from ventricular arrhythmias. There are two
orms of the disease, one autosomal dominant and the other
ecessive (48). The autosomal dominant form is far more
ommon, and the rare recessive form is associated with
eafness. Clinically, the syndrome is characterized by syn-
opal episodes, malignant ventricular tachycardia, and fibril-
ation. The majority of patients with LQTS are asympto-
atic and are either discovered incidentally based on ECG,
amily history, or having survived an episode of syncope or
evere ventricular arrhythmias. The prognosis of untreated
atients is considered to be quite poor. It is claimed that
bout one-fifth of untreated patients presenting with syn-
ope die within 1 year and 50% within 10 years (13). Long
T syndrome can also be acquired due to a long list of
rugs, primarily antiarrhythmics, antidepressants, and phe-
othiazides. In addition, electrolyte imbalance such as
ypokalemia, hypomagnesemia, and hypocalcemia, can also
ause LQTS. These drugs and electrolyte abnormalities play
major triggering role in ventricular arrhythmias and SCD
n patients with the inherited LQTS.
athogenesis of familial LQTS. Long QT syndrome is
ow known to be due to nine different genes (Table 2). Of the
ine genes identified, seven encode potassium channel sub-
nits, one, a sodium channel, and, most recently, a mutation
ncoding for ankyrin B, a scaffolding protein. The latter is the
nly non-channel disease gene thus far described (49).
In LQTS, prolongation of the AP (Fig. 2) may be due to
n increase in the phase of depolarization or a decrease in
he current that induces repolarization. The molecular
efect is determined by the specific genotype, but the final
ommon pathway is prolongation of the AP and decreased
epolarization reserve (47). This results in diminished ability
f the ventricular myocyte to respond to stress such as
ypoglycemia, hypomagnesemia, and drugs that prolonged
he AP. The sodium and potassium channels share opposite
Table 2. Genetic Loci Responsible for Long Q
Arrhythmia Chromosome
Autosomal
LQT1 Ilp15
LQT2 7q35
LQT3 3p21
LQT4 4q25
LQT5 21q22
LQT6 21q22
LQT7 17
Recessive
LQT Ilp15
LQT 21q22ffects on the AP duration. The sodium channel depolarizes ahe cell with most of the activity occurring during the
pstroke of the AP. An increased amount of current active
uring the plateau phase would prolong depolarization and
engthen the AP. Potassium channels when active tend to
estore the internal negativity of the cell and shorten the
P. If potassium currents predominate during the plateau,
epolarization will occur shortening the AP as opposed to
odium currents if they predominate during plateau, it
rolongs the AP. In LQTS due to defects in a potassium
hannel, there is a loss-of-function, whereas in LQTS due
o defects in sodium channel gene, there is a gain-of-
unction. Both are due to autosomal dominant patterns of
nheritance indicating only one copy of the mutated gene is
ecessary to produce the clinical syndrome.
The pathogenesis of LQTS due to defects in the ion
hannels may be summarized as follows: mutations in the
otassium channel lead to inadequate opening and decreased
utward current; mutations in the sodium channels lead to
nadequate closing of the channels and excessive sodium
nward current. This results in an imbalance with an inade-
uate maintenance of the electrical gradient reflected in pro-
ongation of the AP reflected by long QT interval on the
CG.
enotype-phenotype correlations. The role of genetics
ith respect to prognosis and therapy for LQTS remains to
e defined. Studies relating a single mutation to survival or
o clinical events as well as therapy have not shown a
lear-cut stratification (50). This may, in part, relate to lack
f adequate sample size and the genetic background on
hich that particular mutation is interacting. Attempts,
owever, to relate a particular gene to survival and how it
nteracts with gender and the duration of the QT interval
ave been performed (48). In the study by Priori et al. (48),
nvestigators assess the risk of the first cardiac event before
he age of 40 years and before initiating therapy in 580
atients. The study involved 355 patients with a mutation in
he KCNQ1 gene, 176 patients with a mutation in the
CNH2 gene, and 49 individuals with a mutation in the
CN5A gene. These represent the most common causes of
he familial LQTS. Results, as illustrated in Figures 3A, 3B,
yndrome
Gene Frequency
inant Loci
KCNQI 50%
KCNH2 30%–40%
SCN5A 5%–10%
ANK2 Rare
KCNEI Rare
KCNE2 Rare
KCNJ2 Rare
Deafness)
KCNQI Rare
KCNQ2 RareT S
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Genomics and Cardiac Arrhythmias January 3, 2006:9–21uite different among the three groups with the highest
vent rate occurring in KCNH2 and SCN5A. Analysis for
ender within each subgroup showed that gender had no
nfluence on patients with a mutation in the KCNH2 gene,
hereas female patients with a mutation in the KCNH2
ene had a higher risk than male patients, and there was a
rend towards a higher risk among patients with a mutation
n the SCN5A. Thus, a first cardiac arrest or sudden death
as highest among female patients with a mutation in the
CNH2 gene (0.82 per year) and male patients with a
utation in the SCNA5 gene (0.96 per year). Thus, the role of
ender varies according to the genetic locus. Correcting for the
T interval showed significant differences among the three
ubgroups. The mean QT was 466  44 ms among patients
ith a mutation at the KCNQ1 gene, 490  49 ms among
hose with a mutation in the KCNH2 gene, and 496 49 ms
mong those with mutations in the SCN5A gene. In each
ubgroup, the QT interval was longer in those who were
ymptomatic. The number of genetically affected patients with
normal QT interval was significantly higher in the KCNQ1
roup (36%) than in the KCNH2 group (19%) or the SCN5A
roup (10%). Analysis of the event-free survival, taking into
ccount the quartile of corrected QT interval, showed progres-
igure 2. Schematic of inward and outward ionic currents, pumps, and exc
eart. Control and failing (bold line) action potential profiles are shown o
schematic of the time course of each current is shown, and the gene pr
ermission from Fuster V, Alexander RW, O’Rourke RA. Hurst’s The Hive decrease in survival at longer QTc values. These data sllustrate an interaction of the particular gene with gender and
he duration of the QT interval.
ENETIC IMPLICATIONS FOR THE
HERAPEUTIC MANAGEMENT OF LQTS
espite the large number of mutations (300) responsible for
QTS, there is still limited correlation with respect to specific
herapy. It is evident that mutations in the KCNH2 or
CN5A genes are associated with more cardiac events. Given
he risk stratification provided by the three parameters previ-
usly discussed, the investigators (48,50) recommend that
rophylactic treatment is warranted in male and female pa-
ients with a mutation in the KCNQ1 gene who have a QT
bove 500 ms or more, male patients with a mutation in the
CNH2 gene who have a QT of 500 ms or more, all female
atients with a mutation at the KCNH2 gene irrespective of
he QT, and all patients with a mutation in the SCN5A gene.
Schwartz et al. (51,52) reported cardiac events more
requently occur during exercise (62%) and only rarely
uring sleep and rest in LQT1 patients. Swimming is also a
ommon trigger in the LQT1 syndrome (52). In contrast, in
QT3 patients, cardiac events predominantly occur during
ers that underlie atrial and ventricular action potentials in the mammalian
. Each phase of the action potential is labeled. Under the action potential,
(probable clone) that underlies the current is indicated. Reprinted with
11th edition. McGraw-Hill Companies, 2004.hang
n topleep and rest (39%) while exercise-induced events are rare
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January 3, 2006:9–21 Genomics and Cardiac Arrhythmias51). In LQT2 patients, cardiac events occur equally during
xercise or rest (51). Interestingly, a subtle startle in a form
f auditory stimulus is more likely to precipitate arrhythmias
n LQT2. Exercise or mental stress more often triggers
entricular arrhythmias in LQT4 patients (49). In LQT7,
ypokalemia is more likely to trigger ventricular arrhythmias
igure 3. Kaplan-Meier estimates of cumulative survival free of cardiac
vents among the 580 patients with the long QT syndrome in the risk
tratification analysis, according to gender and the QT interval corrected
or heart rate (QTc), in the group with a mutation at the LQT1 locus (A),
he group with a mutation at the LQT2 locus (B), and the group with a
utation at the LQT3 locus (C). Printed with permission from N Engl
Med 2003;348:1866–74.s well as periodic paralysis. Thus, patients with these apecific syndromes can be advised to avoid this form of
ctivity. Several studies have concluded that beta-blockers
re far more effective in LQT1 than LQT2 or LQT3.
ecause it is more common to have a lethal event in LQT3
han in LQT1 or LQT2, some have suggested that an ICD
mplantation is to be encouraged in patients with LQT3
yndrome (53). In 2002, Moss et al. (52) suggested LQT2
atients with mutations in the pore region of the KCNH2
ene have increased risk of arrhythmias over that of muta-
ions in the non-pore region. This has been disputed by
areba et al. (54), but a more recent Japanese study reports
ndings similar to that of Moss et al. (55). Many patients
ith LQTS do not respond to beta-blockers or other forms
f drug therapy and thus would be candidates for an ICD.
evertheless, in asymptomatic patients with borderline
rolonged QT, the decision remains difficult to insert an
CD. The investigators strongly recommend that instituting
herapy in patients at low risk of becoming symptomatic
efore the age of 40 years should be individualized. Further
tudies are required in such patients before a robust recom-
endation can be developed.
HE ROLE OF GENETICS IN DRUG-INDUCED LQTS
ong QT syndrome as a cause for ventricular tachycardia
nd sudden death is more commonly associated with ac-
uired disorders than that of the familial LQTS. A major
ause of acquired long QT is drugs (56). The predominant
echanism whereby the QT interval is prolonged, whether
t be genetic or acquired, is prolongation of sodium influx or
ore commonly delayed outflux of potassium ions. There
re over 20 potassium channels expressed in the heart, most
f which participate in the AP (57). Antiarrhythmic drugs
an also induce long QT primarily those in class 1A (e.g.,
uinidine) or class 3 (e.g., sotolal). Of the 25 drugs for
hich a mechanism has been elucidated, 24 of them are
lockers of the potassium channel, which delays repolariza-
ion. It is well recognized these drugs induce prolonged QT
nly in individuals who are susceptible. It is the aim of
harmacogenetics and pharmacogenomics to determine the
enetic basis for this susceptibility. One obvious avenue of
nvestigation is to determine whether these susceptible
ndividuals have a mutation in one of the channel proteins
hat is aggravated by drugs. The extent to which this occurs
emains to be determined as screening for familial long QT
utations remains experimental and time-consuming. A
ecent study showed 10% to 15% of individuals with
rug-induced LQTS harbor ion channel gene mutations or
NPs that predispose to the LQTS (58). Most of the
utations or SNPs found so far that predispose to long QT
re in the potassium channels (59). Gene variants associated
ith acquired arrhythmias according to Anantharam et al.
60) can be classified as indirect, direct, and compound.
ndirect are mutations that impair the potassium channel at
aseline but do not affect drug sensitivity and are not
ssociated with any prolongation of the QT interval until
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Genomics and Cardiac Arrhythmias January 3, 2006:9–21rug administration is superimposed upon this inherited
mpairment. An example would be A116V-MIRPI with
uinidine (61). Another example is an Asian-specific SNP
G643S) in the KCNQ1 gene, which has been shown to
nduce LQTS (62). The prevalence of G643S is 11% in the
apanese population and was first identified after a patient
eing on a class 1A antiarrhythmia agent. Another example
f an SNP predisposing to prolonged long QT, which
ppears to be ethnic-related, is that of the S1102Y SNP
ound more commonly in the African population (63). This
NP in the SCN5A gene increases the risk of cardiac
rrhythmias in the presence of drugs such as amiodarone. It
s found primarily in West African, Caribbean, and African
merican populations. It does not in itself cause LQTS but
nly in the presence of other aggravating factors.
Direct mutations are perhaps the most difficult because
hey do not affect potassium current but increase sensitivity
o drug blockade (64). An example of this is T8A-MIRPI
NP present in 1.6% of the U.S. population was first
dentified in a patient taking a combination of sulfamethox-
zole and trimethoprim. This SNP increases the sensitivity
f the sodium channel to blockage by the sulfa drugs. The
hird category compound mutations are those that impair
hannel function at baseline and also increase sensitivity to
he drug. An example is the Q9E MIRPI channel, which
as discovered in a female patient after taking clarithromy-
in, which precipitated torsades de pointes. Women are
ore vulnerable to develop prolonged QT than men if
aused by drugs that block the potassium channel (64).
ltimately, if we are to avoid sudden death associated with
rolonged QT, it will be necessary to screen for all known
utations and SNPs that predispose to long QT.
An equally fruitful area is the role of heredity with respect
o the pharmacokinetics of these drugs. Most of these drugs
re eliminated from the bloodstream by the cytochrome
YP2D6 system in the liver which again, depending on
hich particular polymorphism is inherited, can increase or
ecrease the blood concentration of that particular drug.
ltimately, it will be possible to determine whether some-
ne is a rapid or slow acetylator of these drugs, and the
ppropriate drug dose can be modified. It is well recognized
n the case of procainamide that fast acetylators of this drug
re less likely to develop the lupus syndrome (56). Similar
tudies are well recognized for the development of neurop-
thy in response to isoniazid therapy (56).
QTS
his is a rare disease associated with accelerated atrial and
entricular depolarization and a high propensity for atrial and
entricular arrhythmias (13). Mutations have been identified in
hree genes, all of which are a gain-of-function. The syndrome
sually occurs in structurally normal hearts. The syndrome is
ecognized by a short QT on the surface ECG. Three loci have
een identified referred to as SQTS1 and SQTS2 and SQTS3
65); SQTS1 is caused by a gain-of-function mutation in the eCNH2 gene encoding an alpha subunit of the potassium
hannel. The SQTS2 is caused by a gain-of-function mutation
n the KCNQ1 gene encoding the alpha subunit of the
otassium channel. The SQTS3 was reported recently (65) due
o a gain-of-function mutation in the KCNH2 gene encoding
or the inwardly rectifying potassium channel, which acceler-
tes repolarization and shortens the AP duration. It is of some
hysiological significance that a loss of function mutation in
hese genes is associated with the opposite effect, namely,
elayed repolarization, which induces familial LQTS. The
echanism for arrhythmias in the SQTS is yet to be deter-
ined. The prevalence of the SQTS has, until recently, been
onsidered rare. There is increasing evidence that many cases
f ventricular fibrillation and SCD previously considered idio-
athic may be due to SQTS. A rare disease referred to as
nderson syndrome (66) is due to a loss-of-function mutation
n the gene encoding for a potassium channel subunit, which is
ssociated with muscle paralysis, long QT, and ventricular
rrhythmias. It is of interest that quinidine, a drug that
rolongs the QT interval, has been shown to favorably affect
his disease and is recommended as treatment to prevent
alignant arrhythmias.
AMILIAL CATECHOLAMINERGIC
OLYMORPHIC VENTRICULAR TACHYCARDIA
his is inherited in autosomal dominant and recessive forms
ccurring without evidence of structural myocardial disease
67,68). It is characterized by bidirectional and polymorphic
entricular tachycardia in response to vigorous exercise. This
requently deteriorates into ventricular fibrillation and
eath. Patients usually present with recurrent syncope,
eizures, or sudden death after physical activity or emotional
tress (69). The mortality is significant approximating 30%
y age 30 years (67,70). The first family was mapped to
q42–43 (67), and missense mutations were identified in
he gene encoding ryanodine receptor 2 (68). Subsequently,
utations responsible for this disease were also shown to be
resent in calsequestrin 2 (71). Thus, both genes are
nvolved with the release and handling of calcium.
The mechanism whereby these defects induce ventricular
achycardia remains to be determined. It is well established
hat the ectopic beats are initiated in discrete regions of the
picardium. A recently proposed mechanism by Nam et al.
72) suggests delayed afterdepolarization induces extrasys-
olic activity, which triggers ventricular tachycardia under
onditions of defective calcium handling. The origin of the
ctopic beats in the epicardium increases transmural disper-
ion, which provides a substrate for re-entrant tachyarrhyth-
ias. The reason for the ectopics originating in the epicar-
ium is unknown but postulated to be because of the greater
ensity of sarcoplasmic reticulum calcium content in the
picardium. The choice of treatment is a beta-blocker.
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January 3, 2006:9–21 Genomics and Cardiac ArrhythmiasISSUE GENE PROFILING USING MICROARRAYS TO
EARCH FOR GENES THAT INDUCE OR PREDISPOSE
O VENTRICULAR AND ATRIAL ARRHYTHMIAS
he human genome is estimated to contain about 25,000
istinct genes. Identification of these genes and their func-
ion remains to be determined. Regulation of gene expres-
ion, recognized to play a major role in the response of the
ody to environmental stimuli including disease, is of
ritical importance in the diagnosis and treatment of disease.
enetic regulation of organ differentiation is perhaps even less
nderstood. DNA or RNAmicroarray (73,74), a relatively new
echnique consisting of thousands of genes etched into a chip,
an be used to identify genes via hybridization to complimen-
ary base pairing. Microarray chips are now available with
ssentially all of the genes represented by expressed sequence
ag or oligonucleotide. This technique is being utilized to
etermine which genes are expressed in certain tissues and the
xtent to which their expression is regulated in response to a
ariety of stimuli. It is well recognized in animal models and in
uman disease that atrial fibrillation, once it occurs, tends to be
elf-perpetuating and is associated with significant tissue re-
odeling of the atria (75). Studies being performed in the goat
76) and in human atrial tissue removed at the time of surgery
77) show a distinct gene expression profile associated with
trial remodeling in response to atrial fibrillation. A variety of
enes have been observed to be up-regulated while others are
own-regulated during this remodeling process (78). It has also
een shown in animal models that once atrial fibrillation is
onverted to sinus rhythm, this pattern will return to that of the
ormal atrium (76). This provides an opportunity to assess
hese genes for polymorphisms as well as perform genomic
unction analysis to determine genes that play a pathogenic role
n sustaining atrial fibrillation. Such studies, while in their
rimitive state, are ongoing. Another area of interest is atrial
brillation that occurs after cardiac surgery in about 20% of
ndividuals (77). Are they predisposed to genetic factors? The
bility to scan with a chip containing 25,000 genes should
ccelerate finding genes pivotal to the disease.
Similarly, it is well recognized that ventricular hypertrophy
ncreases one’s risk of sudden death two- to four-fold regardless
f the stimulus (18). The mechanism whereby ventricular
ypertrophy increases risk to arrhythmias have not been deter-
ined. It is thus reasonable to assume that certain genes with
olymorphisms that predispose to sudden death may be up-
egulated in hypertrophy, which accounts in part for the
ulnerability to arrhythmias. Microarray analysis, again, has
lready shown there is a differential display of genes in the atria
nd ventricle, and with the development of hypertrophy the
etal program of genes is up-regulated along with a variety of
ther genes (18). The microarray also provides the opportunity
o classify genes in clusters as well as identify sets of genes that
lay a role in cell signaling. Thus, if a particular gene with an
NP is shown to be important, one can assess for SNPs in
ther such genes that are part of the signaling network.
evertheless, it will significantly accelerate our ability to relate tnd associate genes with certain responses to the environment
uch as remodeling with atrial fibrillation or hypertrophy in
esponse to ischemic heart disease.
UTURE OF GENOMICS IN
ARDIOVASCULAR ARRHYTHMIAS
hile cardiac arrhythmias may be associated with or
ithout structural heart disease, the defect always involves
ome aspect of the electrical conduction system of the heart.
he structural component is, of course, the sinus node,
pecialized atrial tracts, atrioventricular node, and bundle of
IS with the Purkinje system. After conducting within this
pecialized electrical transmission, the current must pass
nto other cells such as myocytes. The important compo-
ents are predominantly ionic currents, ion channels, struc-
ural proteins, and gap junctions. Most of the genetic
efects currently identified involve some aspect of the
ubunits of the ion channels. We now recognize at least 429
enes that encode ion channel proteins in the human (79).
f these, 170 encode potassium channels, 38 are for calcium
hannels, 29 are for sodium channels, 58 are for chloride
hannels, and 15 are glutemate receptors (80). It is of
nterest that ion channels represent only about 5% of the
olecular targets of modern medicine (81,82). It is now
ecognized that in addition to the role of ion channels
egulating membrane potential they also regulate many
ther functions including cell volume and hormone secre-
ion (83,84). The complexity of these channels, such as the
oltage-gated cardiac potassium channels, is such that
everal domains exist within the integrated channel protein.
n addition to the pore domain, there are the domains that
rovide ion selectivity, opening and closing of the gate
ogether with the sensing units whether it be voltage or
hemical. The elucidation of mutations causing disease is
apidly enhancing our understanding of the topography and
equences involved with each domain. Approaches by the
harmaceutical industry to develop designer drugs for those
omains, while in its infancy, are rapidly developing.
The characteristic feature of the electrical activity of the
eart is the AP of the atria and ventricles due to depolar-
zation and repolarization with the characteristic long pla-
eau phase involving multiple ion channels. Many of these
hannels have now been cloned and will serve as prime
andidates for the identification of genetic defects in the
uture. The major currents involved in the atrial and
entricular AP are indicated in Figure 2. Cardiac electrical
ctivity is thus a complex process, which integrates the
lectrical activity of multiple molecules. Any variant in
ither of these molecules whether it is due to SNPs or
reater defects can significantly alter cardiac activity. It is
ell recognized that structural heart disease, associated with
ither hypertrophy or cardiac dilatation, can structurally
ffect electrical transmission or through altered gene expres-
ion induce arrhythmias. Hypertrophy is well documented
o increase the propensity for SCD by about four-fold.
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Genomics and Cardiac Arrhythmias January 3, 2006:9–21tructural heart disease is associated with excessive fibrous
issue, which has a lower velocity of conduction and could
ead to re-entry arrhythmias. Common genetic variants have
een shown to increase the risk of cardiac arrhythmias, and
ost recent studies show that even common genetic variant
n genes referred to as SNPs can alter cardiac electrical
anifestations in certain populations. Atrial fibrillation is
ssociated with significant morbidity in the aging popula-
ion. Ventricular fibrillation is a lethal arrhythmia respon-
ible for over 600,000 deaths each year in the Western
orld. Both atrial and ventricular fibrillation remain the
ost challenging of rhythm disorders.
eprint requests and correspondence: Dr. Robert Roberts,
niversity of Ottawa Heart Institute, 40 Ruskin Street, Ottawa,
ntario, K1Y 4W7 Canada. E-mail: rroberts@ottawaheart.ca.
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